SPECIAL FEATURE - Platform Technologies - Derisking & Transforming Drug Development September 29, 2017

Contributor Cindy H. Dubin, in this second annual report, speaks with several exciting and innovative companies whose platform technologies are transforming drug development.

TG Therapeutics Announces Completion of Target Enrollment in Phase 3 Trial September 11, 2017

CONTRACT MANUFACTURING - Delivering Market Success & ROI to Pharmaceutical Partners May 31, 2017

Mike Schaefers, PhD, and Mike Treadaway say more than ever, contract manufacturing must deliver continuous innovation and flexibility to accommodate the delivery of a wide range of drugs throughout each therapy’s lifecycle.

SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: A Rise in Biologics & Improved Technology Give Pharma Reasons to Consider Parenteral Delivery May 2, 2017

Contributor Cindy H. Dubin speaks with some of the leading companies in this market to find out about key trends, packaging advancements, safety improvements, and technology developments.

SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017

Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.

PLATFORM TECHNOLOGY - ​​The 3DNA® Platform for Targeted Drug Delivery November 7, 2016

Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.

SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016

Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.

PHARMACOLOGY MODELS - Early Phase Pharmacodynamic Models for Respiratory Drug Candidates June 30, 2016

Robert Lins, MD, PhD, believes classical primary respiratory endpoints are far from successful in exploratory and confirmatory studies, and new techniques being developed have most potential in early phase, exploratory, clinical trials, but there may be the opportunity to apply at least some of them in the later stages of development.

DELIVERY PLATFORM - Encochleated Drug Formulations: Enhancing Efficacy, Minimizing Toxicity June 30, 2016

Roelof Rongen, MBA, MS, indicates drugs for serious fungal and microbial infections currently require IV administration at doses associated with significant toxicity. Orally administered, encochleated formulations of a broad-spectrum of fungicidal and anti-microbial medications may provide delivery of anti-infective drugs at therapeutic levels while minimizing drug-associated side effects.

Argos Therapeutics Enters Strategic Research Agreement With Adaptive Biotechnologies June 20, 2016

DRUG DEVELOPMENT EXECUTIVE - Crown Bioscience: Enhancing the Drug Development Process May 31, 2016

Jean Pierre Wery, President of Crown Bioscience, discusses the requirement for more accurate research models in oncology research, focusing on PDX models that have the ability to more adequately represent the conditions and mechanisms of immunotherapy in human patients.

SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Using a Single Provider Reduces Costs & Risk March 30, 2016

Contributor Cindy H. Dubin highlights several CDMOs that are evolving their models to become their clients’ single provider and to accommodate their more potent, challenging products.

JDRF & Sanofi USAnnounce Expansion of Collaboration March 1, 2016

MICRONEEDLE TECHNOLOGY - The New Potential of Microneedles for Biologics & Small Molecules November 18, 2015

Lisa A. Dick, PhD, describes how microneedle technology is being applied in two new transdermal systems using solid and hollow microneedles, which have the ability to deliver small molecules as well as biologics, opening up the potential for self-administration of a broad array of APIs

EXECUTIVE INTERVIEW - Terumo: Innovating at the Speed of Life for Cutting-Edge Solutions in Medical Devices & Services August 31, 2015

Mr. Juichi “Jim” Takeuchi, Terumo Corporation’s Executive Officer and President of Global Pharmaceutical Solutions, discusses his company’s innovative approach to parenteral drug delivery using integrated science and technology.

SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Anticipating the Needs of the Future May 5, 2015

Contributor Cindy H. Dubin speaks with several companies in the prefilled syringe and parenteral manufacturing market that are offering a range of services and systems that cater to today’s issues as well as anticipating the needs of the future.

LIPID-BASED DELIVERY SYSTEMS - New Approaches for Macromolecule Oral Delivery, Abuse Deterrence & Bioavailability Enhancement March 31, 2015

Julien Meissonnier reviews the development of a broad range of advanced oral drug delivery technologies, including a toolkit of technologies based upon the broad application of lipid-based drug delivery systems for optimum solubility enhancement.

REGULATORY GUIDANCE - Staying on Top of FDA Guidance for Industry - Training Webinars Foster Transparency & Collaboration March 2, 2015

Frost & Sullivan recently tuned into three webinars that were considered to be particularly relevant to current hot topics and therapy areas, and then reviews the current trends and needs behind each new or revised guidance document and key insights for potential sponsors.

SPECIAL FEATURE - Analytical Testing: A Critical Element in Drug Development January 8, 2015

Contributor Cindy H. Dubin interviews several industry experts who believe there is intense competition to develop cutting-edge therapies and get them through development quickly to take advantage of patent exclusivity. And one of the critical elements in the drug development process is analytical testing.

GLOBAL DELIVERY MARKET - Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier November 19, 2014

Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.